Lung sclerosing hemangioma

Summary

Lung sclerosing hemangioma (MONDO:0006280) is a disease. A subtype of hemangioma of lung — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung sclerosing hemangioma
Mondo ID	MONDO:0006280
EFO	EFO:1000337
MeSH	D047868
DOID	DOID:495, DOID:5766
NCIT	C5656
SNOMED CT	707365008
UMLS	C1509148
MedGen	734262
Is cancer (heuristic)	no

Also known as: lung sclerosing angioma · lung sclerosing hemangioma · Pneumocytoma · sclerosing angioma of lung · sclerosing angioma of the lung · sclerosing hemangioma of lung · sclerosing hemangioma of the lung · sclerosing Pneumocytoma

Disease family

This is a subtype of hemangioma of lung. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › respiratory system benign neoplasm › lung benign neoplasm › hemangioma of lung › lung sclerosing hemangioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.